Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
3.690
+0.240 (6.96%)
Jun 26, 2026, 12:35 PM EDT - Market open
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$486,127
Profits / Employee
-$1,901,559
Market Cap
324.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 24 | 30.77% |
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Silence Therapeutics | 88 |
| Upstream Bio | 75 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 59 |
| Atea Pharmaceuticals | 55 |
| X4 Pharmaceuticals | 45 |
VSTM News
- 2 days ago - Verastem Transcript: Study update - Transcripts
- 2 days ago - Verastem Press release: Study update - Filings
- 2 days ago - Verastem Slides: Study update - Filings
- 2 days ago - Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial - TheFly
- 2 days ago - VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors - Business Wire
- 2 days ago - Verastem price target lowered to $8 from $15 at Jefferies - TheFly
- 9 days ago - Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study - TheFly
- 9 days ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer - Business Wire